<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01839331</url>
  </required_header>
  <id_info>
    <org_study_id>AP-003-A</org_study_id>
    <nct_id>NCT01839331</nct_id>
  </id_info>
  <brief_title>AP-003-A A Efficacy and Safety Study of Two Doses of Intra-Articular Injection of Ampion™ in Adults With Pain Due to Osteoarthritis of the Knee</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Two Doses of Intra-Articular Injection of Ampion™ in Adults With Pain Due to Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ampio Pharmaceuticals. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ampio Pharmaceuticals. Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of two doses of Intra-Articular Injection of Ampion™ in&#xD;
      Adults with pain due to osteoarthritis of the knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of&#xD;
      two Doses of Intra-Articular Injection of Ampion™ in Adults with pain due to osteoarthritis&#xD;
      of the knee.&#xD;
&#xD;
      The primary trial objective is to evaluate the greater efficacy of 10 mL Ampion™ versus 10 mL&#xD;
      placebo than 4 mL Ampion™ versus 4 mL placebo intra-articular (IA) injection in improving&#xD;
      knee pain, when applied to patients suffering from OA of the knee.&#xD;
&#xD;
      The secondary trial objective include: the evaluation of the safety of an intra-articular&#xD;
      injection of Ampion™ when applied to patients suffering from OA of the knee, evaluation of&#xD;
      the efficacy of intra-articular injection of Ampion™ and placebo on stiffness and function&#xD;
      when applied to patients suffering from OA of the knee and evaluation of responder status&#xD;
      defined by the Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research&#xD;
      Society International (OMERACT-OARSI) Criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in knee pain</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in stiffness and function, defined by the Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (MERACT-OARSI) Criteria</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">329</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Low Dose Ampion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mL Ampion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 mL placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Ampion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mL Ampion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mL Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 ml Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Ampion</intervention_name>
    <description>4 mL Ampion</description>
    <arm_group_label>Low Dose Ampion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Ampion</intervention_name>
    <description>10 mL Ampion 10mL</description>
    <arm_group_label>High Dose Ampion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Low Dose 4 mL</intervention_name>
    <description>4 mL Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 10 mL</intervention_name>
    <description>Placebo 10 mL</description>
    <arm_group_label>10 mL Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide written informed consent to participate in the study&#xD;
&#xD;
          -  Willing and able to comply with all study requirements and instructions of the site&#xD;
             study staff&#xD;
&#xD;
          -  Male or female, 40 years to 85 years old (inclusive)&#xD;
&#xD;
          -  Must be ambulatory&#xD;
&#xD;
          -  Index knee must be symptomatic for greater than 6 months with a clinical diagnosis of&#xD;
             OA and supported by radiological evidence Kellgren Lawrence Grade II to IV) that is&#xD;
             not older than 6 months prior to the date of screening&#xD;
&#xD;
          -  Moderate to moderately-severe OA pain in the index knee (rating of at least 1.5 on the&#xD;
             WOMAC Index 3.1 5-point Likert Pain Subscale) assessed at screening&#xD;
&#xD;
          -  Moderate to moderately-severe OA pain in the index knee (even if chronic doses of&#xD;
             nonsteroidal anti-inflammatory drug (NSAID), which have not changed in the 4 weeks&#xD;
             prior to screening, have been/are being used)&#xD;
&#xD;
          -  No analgesia (including acetaminophen [paracetamol]) taken 12 hours prior to an&#xD;
             efficacy measure&#xD;
&#xD;
          -  No known clinically significant liver abnormality e.g. cirrhosis, transplant, etc.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  As a result of medical review and screening investigation, the Principal Investigator&#xD;
             considers the patient unfit for the study&#xD;
&#xD;
          -  A history of allergic reactions to human albumin (reaction to non-human albumin such&#xD;
             as egg albumin is not an exclusion criterion)&#xD;
&#xD;
          -  A history of allergic reactions to excipients in 5% human albumin (N-acetyltryptophan,&#xD;
             sodium caprylate)&#xD;
&#xD;
          -  Presence of tense effusions&#xD;
&#xD;
          -  Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or&#xD;
             joint replacement in the affected knee, as assessed locally by the Principal&#xD;
             Investigator&#xD;
&#xD;
          -  Isolated patella femoral syndrome, also known as chondromalacia&#xD;
&#xD;
          -  Any other disease or condition interfering with the free use and evaluation of the&#xD;
             index knee for the duration of the trial e.g. cancer, congenital defects, spine OA)&#xD;
&#xD;
          -  Major injury to the index knee within the 12 months prior to screening&#xD;
&#xD;
          -  Severe hip OA ipsilateral to the index knee&#xD;
&#xD;
          -  Any pain that could interfere with the assessment of index knee pain (e.g. pain in any&#xD;
             other part of the lower extremities, pain radiating to the knee)&#xD;
&#xD;
          -  Any pharmacological or non-pharmacological treatment targeting OA started or changed&#xD;
             during the 4 weeks prior to randomization or likely to be changed during the duration&#xD;
             of the study&#xD;
&#xD;
          -  Use of the following medications:&#xD;
&#xD;
               1. No IA injected pain medications in the study knee during the study&#xD;
&#xD;
               2. No analgesics containing opioids. NSAIDs may be continued at levels preceding the&#xD;
                  study and acetaminophen is available as a rescue medication during the study from&#xD;
                  the provided supply&#xD;
&#xD;
               3. No topical treatment on osteoarthritis index knee during the study&#xD;
&#xD;
               4. No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study&#xD;
                  (treatment such as Aspirin and Plavix are allowed)&#xD;
&#xD;
               5. No systemic treatments that may interfere with safety or efficacy assessments&#xD;
                  during the study&#xD;
&#xD;
               6. No immunosuppressants&#xD;
&#xD;
               7. No use of corticosteroids &gt; 10 mg prednisolone equivalent per day (if ≤ 10 mg&#xD;
                  prednisolone, the dose must be stable)&#xD;
&#xD;
          -  Any human albumin treatment in the 3 months before randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vaughan Clift, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ampio Pharmaceuticals. Inc.</affiliation>
  </overall_official>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 22, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2013</study_first_posted>
  <disposition_first_submitted>June 18, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>June 18, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 20, 2019</disposition_first_posted>
  <last_update_submitted>June 18, 2019</last_update_submitted>
  <last_update_submitted_qc>June 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>osteoarthrisis of the knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

